1. PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database
   Xiayang Ren et al, 2024, Expert Opinion on Drug Safety CrossRef
2. Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
   Xiaonan Zhang et al, 2024, eBioMedicine CrossRef
3. Safety of PARP inhibitors as maintenance therapy in ovarian cancer
   Sabrina Chiara Cecere et al, 2023, Expert Opinion on Drug Safety CrossRef
4. Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data
   Michael Friedlander et al, 2023, American Society of Clinical Oncology Educational Book CrossRef
5. Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC)
   Walaa Bayoumie El Gazzar et al, 2023, Journal of Oncology Pharmacy Practice CrossRef